Emerging therapies targeting growth factors in hepatocellular carcinoma

References

• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi: 10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi: 10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/s0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi: 10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1(8):EVIDoa2100070.
   PubMedGoogle Scholar
• Dhanasekaran R, Suzuki H, Lemaitre L, et al. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making. Hepatology. 2023. doi: 10.1097/hep.0000000000000513
   PubMedGoogle Scholar
• Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13(3):267–276. doi: 10.1038/cmi.2016.3
   PubMed Web of Science ®Google Scholar
• Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7(1):267. doi: 10.1186/s40425-019-0749-z
   PubMed Web of Science ®Google Scholar
• Hanada K, Perry-Lalley DM, Ohnmacht GA, et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001;61(14):5511–5516.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi: 10.1158/0008-5472.Can-18-3962
   PubMed Web of Science ®Google Scholar
• Odenthal J, Takes R, Friedl P. Plasticity of tumor cell invasion: governance by growth factors and cytokines. Carcinogenesis. 2016;37(12):1117–1128. doi: 10.1093/carcin/bgw098
   PubMed Web of Science ®Google Scholar
• Awuah PK, Nejak-Bowen KN, Monga SP. Role and regulation of PDGFRα signaling in liver development and regeneration. Am J Pathol. 2013;182(5):1648–1658. doi: 10.1016/j.ajpath.2013.01.047
   PubMed Web of Science ®Google Scholar
• Suzuki A, Iwama A, Miyashita H, et al. Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells. Development. 2003;130(11):2513–2524.
   PubMed Web of Science ®Google Scholar
• Wolf HK, Zarnegar R, Michalopoulos GK. Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology. 1991;14(3):488–494. doi: 10.1002/hep.1840140314
   PubMed Web of Science ®Google Scholar
• Duncan SA. Mechanisms controlling early development of the liver. Mech Dev. 2003;120(1):19–33. doi: 10.1016/s0925-4773(02)00328-3
   PubMed Web of Science ®Google Scholar
• Petrillo S, Manco M, Altruda F, et al. Liver sinusoidal endothelial cells at the crossroad of iron overload and liver fibrosis. Antioxid Redox Signaling. 2020;35(6):474–486. doi: 10.1089/ars.2020.8168
   PubMed Web of Science ®Google Scholar
• Kubo N, Araki K, Kuwano H, et al. Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol. 2016;22(30):6841–6850. doi: 10.3748/wjg.v22.i30.6841
   PubMed Web of Science ®Google Scholar
• Mueller SN, Germain RN. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol. 2009;9(9):618–629. doi: 10.1038/nri2588
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi: 10.1038/nrc.2016.73
   PubMed Web of Science ®Google Scholar
• Eun JW, Yoon JH, Ahn HR, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond). 2023;43(4):455–479.
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6 Suppl 16):15–18. doi: 10.1053/sonc.2002.37263
   PubMed Web of Science ®Google Scholar
• Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol. 2017;9(2):106–126. doi: 10.1177/1758834016676703
   PubMed Web of Science ®Google Scholar
• Lee YJ, Karl DL, Maduekwe UN, et al. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res. 2010;70(21):8357–8367. doi: 10.1158/0008-5472.Can-10-1138
   PubMed Web of Science ®Google Scholar
• Vaahtomeri K, Karaman S, Mäkinen T, et al. Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev. 2017;31(16):1615–1634. doi: 10.1101/gad.303776.117
   PubMed Web of Science ®Google Scholar
• Li J, Zhou W, Chen W, et al. Mechanism of the hypoxia inducible factor 1/hypoxic response element pathway in rat myocardial ischemia/diazoxide post‑conditioning. Mol Med Rep. 2020;21(3):1527–1536. doi: 10.3892/mmr.2020.10966
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hanbali A, Cotant M, et al. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2009;115(21):4895–4906.
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg. 2003;238(1):9–28. doi: 10.1097/01.sla.0000075047.47175.35
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19(4):1207–1225. doi: 10.1200/jco.2001.19.4.1207
   PubMed Web of Science ®Google Scholar
• Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071–1121. doi: 10.1152/physrev.00038.2010
   PubMed Web of Science ®Google Scholar
• Wu E, Palmer N, Tian Z, Rutherford S, et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLOS One. 2008;3(11):e3794. doi: 10.1371/journal.pone.0003794
   PubMed Web of Science ®Google Scholar
• Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013;11:97. doi: 10.1186/1478-811x-11-97
   PubMed Web of Science ®Google Scholar
• Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912–920. doi: 10.1158/1078-0432.Ccr-18-1254
   PubMed Web of Science ®Google Scholar
• Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8(9):16052–16074. doi: 10.18632/oncotarget.14109
   PubMedGoogle Scholar
• Tsunoda S, Nakamura T, Sakurai H, et al. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci. 2007;98(4):541–548.
   PubMed Web of Science ®Google Scholar
• Gao L, Wang X, Tang Y, et al. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017;36(1):8. doi: 10.1186/s13046-016-0478-9
   PubMed Web of Science ®Google Scholar
• Lieu C, Heymach J, Overman M, et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17(19):6130–6139. doi: 10.1158/1078-0432.Ccr-11-0659
   PubMed Web of Science ®Google Scholar
• Xie H, Alem Glison DM, Kim RD. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opin Investig Drugs. 2022;31(4):393–400. doi: 10.1080/13543784.2022.2017879
   PubMed Web of Science ®Google Scholar
• Kim RD, Sarker D, Meyer T, et al. First-in-human phase i study of fisogatinib (BLU-554) validates aberrant fgf19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9(12):1696–1707. doi: 10.1158/2159-8290.Cd-19-0555
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhu S, Xu C, et al. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Invest New Drugs. 2023;41(1):162–167. doi: 10.1007/s10637-023-01335-w
   PubMed Web of Science ®Google Scholar
• Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 2014;60(2):442–452. doi: 10.1016/j.jhep.2013.09.009
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6(8):637–645. doi: 10.1038/nrc1912
   PubMed Web of Science ®Google Scholar
• García-Vilas JA, Medina M. Updates on the hepatocyte growth factor/c-met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol. 2018;24(33):3695–3708. doi: 10.3748/wjg.v24.i33.3695
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60.
   PubMed Web of Science ®Google Scholar
• Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther. 2014;7:1927–1932. doi: 10.2147/ott.S46457
   PubMed Web of Science ®Google Scholar
• Satija S, Kaur H, Tambuwala MM, et al. Hypoxia-Inducible Factor (HIF): fuel for cancer progression. Curr Mol Pharmacol. 2021;14(3):321–332.
   PubMed Web of Science ®Google Scholar
• Korbecki J, Simińska D, Gąssowska-Dobrowolska M, et al. Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-κB activation: a review of the molecular mechanisms. Int J Mol Sci. 2021;22(19). doi: 10.3390/ijms221910701
   Web of Science ®Google Scholar
• Liao SH, Zhao XY, Han YH, et al. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. Proteomics. 2009;9(15):3901–3912. doi: 10.1002/pmic.200800922
   PubMed Web of Science ®Google Scholar
• Soni S, Padwad YS. HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol. 2017;56(4):503–515. doi: 10.1080/0284186x.2017.1301680
   PubMed Web of Science ®Google Scholar
• Infantino V, Santarsiero A, Convertini P, et al. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22(11). doi: 10.3390/ijms22115703
   Web of Science ®Google Scholar
• Méndez-Blanco C, Fondevila F, García-Palomo A, et al. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):1–9. doi: 10.1038/s12276-018-0159-1
   PubMed Web of Science ®Google Scholar
• Dong ZZ, Yao M, Wang L, et al. Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem. 2013;13(9):1295–1304. doi: 10.2174/1389557511313090004
   PubMed Web of Science ®Google Scholar
• Cai W, Ma Y, Song L, et al. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K/akt and RAS/raf/ERK signaling pathways. BMC Cancer. 2023;23(1):87.
   PubMed Web of Science ®Google Scholar
• Ngo MT, Jeng HY, Kuo YC, et al. The role of IGF/IGF-1R signaling in hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021;22(4). doi: 10.3390/ijms22041931
   Web of Science ®Google Scholar
• Adamek A, Kasprzak A. Insulin-Like Growth Factor (IGF) system in liver diseases. Int J Mol Sci. 2018;19(5):1308. doi: 10.3390/ijms19051308
   PubMed Web of Science ®Google Scholar
• Xu G, Zhu Y, Liu H, et al. Long non-coding RNA KCNQ1OT1 promotes progression of hepatocellular carcinoma by miR-148a-3p/IGF1R Axis. Technol Cancer Res Treat. 2020;19:1533033820980117. doi: 10.1177/1533033820980117
   Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi: 10.1016/s1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi: 10.1016/s0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi: 10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Yau T, Kaseb A, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(4):310–322. doi: 10.1016/s2468-1253(23)00454-5.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Iwamoto H, Tanaka T, et al. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma. Hepatol Int. 2023. doi: 10.1007/s12072-023-10603-z
   Web of Science ®Google Scholar
• Dorrans B, Llano A. Bevacizumab.Pract Diabetes. 2020;37(2):70–71. doi: 10.1002/pdi.2268
   Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi: 10.1016/j.jhep.2021.11.030.
   PubMed Web of Science ®Google Scholar
• D’Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and child-pugh a and b cirrhosis: a real-world study. Hepatology. 2022;76(4):1000–1012.
   PubMed Web of Science ®Google Scholar
• Kulkarni AV, Tevethia H, Kumar K, et al. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. eClinicalmedicine, 2023. eClinicalMedicine. 2023;63:102179. doi: 10.1016/j.eclinm.2023.102179
   PubMedGoogle Scholar
• Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–870. doi: 10.1016/s1470-2045(15)00050-9
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi: 10.1016/s1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473–488. doi: 10.1016/j.ccell.2020.07.005
   PubMed Web of Science ®Google Scholar
• Ma H, Wei W, Liang D, et al. HGF-Based CAR-T cells target hepatocellular carcinoma cells that express high levels of c-Met. Immunol Invest. 2023;52(6):735–748. doi: 10.1080/08820139.2023.2232402
   PubMed Web of Science ®Google Scholar
• Li K, Qian S, Huang M, et al. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy. Am J Transl Res. 2021;13(1):156–167.
   PubMed Web of Science ®Google Scholar